GSK_Annual_Report_2021

Notes to the Standalone Financial Statements for the year ended March 31, 2021 (contd.) Annual Report 2020-21 117 ( ` in lakhs) As at March 31, 2021 As at March 31, 2020 Note 18 : Other equity Capital redemption reserve 2,61.95 2,61.95 General reserve 790,74.14 790,74.14 Capital reserve 1,65.51 1,65.51 Retained earnings (Including Other Comprehensive Income) 553,51.28 875,61.77 1348,52.88 1670,63.37 Note 19 : Non-current financial liabilities - Borrowings (Unsecured) Interest free deferred sales tax incentive - 2.40 - 2.40 Terms of repayment Interest free deferred sales tax incentive as at March 31, 2021 of ` 2.40 lakhs (March 31, 2020: ` 17.70 lakhs) availed under the 1993 Sales Tax Deferment Scheme which is repayable in one instalment closing on April 30, 2021. The current maturity amount as at March 31, 2021 is ` 2.40 lakhs (March 31, 2020: ` 15.30 lakhs) of the loan has been disclosed under Note 23. ( ` in lakhs) As at March 31, 2021 As at March 31, 2020 Note 20 : Non-current financial liabilities - Others Security deposits received (Unsecured) 2,04.46 2,05.97 Other financial lease liabilities (Refer Note 46) 20,24.99 26,83.72 22,29.45 28,89.69 Note 21 : Non-current provisions For Pricing matters (Refer Note 41 and 26) 122,70.82 122,70.82 For employee benefits (Refer Note 39) Gratuity 16,98.96 24,22.27 Leave encashment and compensated absences 34,94.48 32,07.75 Post retirement medical and other benefits 62,85.22 60,37.58 For long term incentive plan (Refer Note 26 and 52) 2,85.61 3,44.52 For divestment / restructuring (Refer Note 26) 1,92.96 1,92.96 For others (Refer Note 26) 15,96.50 15,73.22 258,24.55 260,49.12